Destiny Pharma PLC Grant of share options (0620O)
08 June 2022 - 4:01PM
UK Regulatory
TIDMDEST
RNS Number : 0620O
Destiny Pharma PLC
08 June 2022
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of share options
Brighton, United Kingdom - 8 June 2022 - Destiny Pharma plc
(AIM: DEST, "the Company") a clinical stage innovative
biotechnology company focused on the development of novel medicines
that can prevent life threatening infections, announces the
following options ("Options") over 190,000 ordinary shares of 1
pence in the Company have been granted under the Destiny Pharma plc
2020 Long Term Incentive Plan (the "Plan") to the following
PDMR.
Name Position Total number Total Options held
of Options after the grant
granted under
award
Chief Medical
Dr Yuri Martina Officer 190,000 190,000
The Options have been granted with an exercise price of GBP0.46
and will vest on 8 June 2025. The Options were granted under award
agreements that incorporated the terms of the Plan.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark / Manel Mateus /Vici Rabbetts
+44 (0) 208 078 4357
DestinyPharma@optimumcomms.com
finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Kate Bannatyne / George Dollemore, Corporate
Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SporCov, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
research projects.
For further information on the company, please visit
www.destinypharma.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Yuri Martina
------------------------------- ----------------------------------
2. Reason for the Notification
-------------------------------------------------------------------
a) Position/status Chief Medical Officer
------------------------------- ----------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Destiny Pharma plc
------------------------------- ----------------------------------
b) LEI 213800O9WH9Z38EHAC95
------------------------------- ----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
-------------------------------------------------------------------
a) Description of the Grant of award of options over
Financial instrument, ordinary shares of 1 pence each
type of instrument ("Ordinary Shares") under the
2020 Destiny Pharma plc Long
Term Incentive Plan.
Identification code DEST GB00BDHSP575
------------------------------- ----------------------------------
b) Nature of the transaction Grant of award of options over
Ordinary Shares under the 2020
Destiny Pharma plc Long Term
Incentive Plan.
------------------------------- ----------------------------------
c) Price(s) and volume(s) GBP0.46 pence exercise price
per Ordinary Share
190,000 Ordinary Shares
------------------------------- ----------------------------------
d) Aggregated information:
Aggregated volume See 4c) above
Price
------------------------------- ----------------------------------
e) Date of the transaction 8 June 2022
------------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
------------------------------- ----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFRMFTMTIMBJT
(END) Dow Jones Newswires
June 08, 2022 02:01 ET (06:01 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024